VAPO - Vapotherm Inc Stock Price, Fair Value and News

1.27USD0.00 (0.00%)Market Closed

Market Summary

USD1.270.00

Market Closed

0.00%

VAPO Stock Price

View Fullscreen

VAPO RSI Chart

VAPO Valuation

Market Cap

7.9M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

0.11

EV/EBITDA

0.05

Price/Free Cashflow

-0.29

VAPO Price/Sales (Trailing)

VAPO Profitability

Operating Margin

41.19%

EBT Margin

-84.56%

Return on Equity

-423.56%

Return on Assets

-74.97%

Free Cashflow Yield

-346.62%

VAPO Fundamentals

VAPO Revenue

Revenue (TTM)

68.7M

Rev. Growth (Yr)

5.74%

Rev. Growth (Qtr)

30.11%

VAPO Earnings

Earnings (TTM)

-58.2M

Earnings Growth (Yr)

52.49%

Earnings Growth (Qtr)

32.68%

Breaking Down VAPO Revenue

Last 7 days

1.6%

Last 30 days

-20.6%

Last 90 days

47.7%

Trailing 12 Months

-69.2%

How does VAPO drawdown profile look like?

VAPO Financial Health

Current Ratio

2.43

VAPO Investor Care

Shares Dilution (1Y)

7.27%

Diluted EPS (TTM)

-9.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	62.9M	66.0M	67.6M	68.7M
2022	102.6M	95.0M	70.4M	66.8M
2021	138.9M	124.4M	132.0M	113.3M
2020	54.9M	78.1M	97.8M	125.7M
2019	43.9M	45.4M	46.8M	48.1M
2018	0	0	0	42.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vapotherm Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 01, 2024	moynihan mary beth	acquired	50,000	10.00	5,000	-
Jan 01, 2024	arnerich anthony l.	acquired	52,500	10.00	5,250	-
Jan 01, 2024	berry lance a	acquired	60,000	10.00	6,000	-
Jan 01, 2024	weatherman elizabeth h	acquired	60,000	10.00	6,000	-
Jan 01, 2024	liken james w	acquired	90,000	10.00	9,000	-
Jan 01, 2024	knowles lori lynn	acquired	47,500	10.00	4,750	-
Jan 01, 2024	spence donald j	acquired	60,000	10.00	6,000	-
Oct 02, 2023	landry john	acquired	-	-	20,000	svp & chief financial officer
Oct 02, 2023	mckay dorota	acquired	-	-	15,000	vp, controller and cao
Oct 02, 2023	lawrence brian	acquired	-	-	30,000	svp & chief technology officer

Which funds bought or sold VAPO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Requisite Capital Management, LLC	sold off	-100	-10,978	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-444,387	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-29,416	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-3,919	-	-%
Feb 14, 2024	Crow's Nest Holdings LP	sold off	-100	-1,419,330	-	-%
Feb 14, 2024	FSA Wealth Management LLC	new	-	1,000	1,000	-%
Feb 14, 2024	Creative Planning	sold off	-100	-35,526	-	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	sold off	-100	-57,712	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-874,801	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-47,278	-	-%

Are Funds Buying or Selling VAPO?

Are funds buying VAPO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VAPO

No. of Funds

Unveiling Vapotherm Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 15, 2024	kent lake capital llc	8.1%	499,619	SC 13G/A
Feb 14, 2024	parian global management lp	6.6%	408,939	SC 13G/A
Feb 14, 2024	crow's nest holdings lp	9.14%	561,001	SC 13G/A
Feb 14, 2024	roystone capital management lp	10.1%	647,561	SC 13G/A
Feb 08, 2024	integrated core strategies (us) llc	7.8%	490,044	SC 13G/A
Nov 02, 2023	kent lake capital llc	5.2%	316,368	SC 13G
Sep 20, 2023	army joseph	8.6%	534,110	SC 13D/A
Feb 17, 2023	roystone capital management lp	10.7%	5,180,495	SC 13G
Feb 14, 2023	crow's nest holdings lp	5.73%	1,630,876	SC 13G/A
Feb 14, 2023	hound partners, llc	0.0%	0	SC 13G/A

Recent SEC filings of Vapotherm Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 01, 2024	8-K	Current Report
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 27, 2024	S-8	Employee Benefits Plan
Feb 27, 2024	8-K	Current Report
Feb 22, 2024	8-K	Current Report
Feb 22, 2024	10-K	Annual Report

Peers (Alternatives to Vapotherm Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.2B	40.3B	-4.83%	-4.47%	32.75	4.57	-2.84%	-3.08%
BDX	67.8B	19.7B	-3.67%	-7.05%	50.87	3.44	4.82%	-17.56%
ALGN	21.7B	3.9B	-7.16%	-5.33%	46.88	5.53	5.72%	46.72%
BAX	18.8B	14.9B	-14.74%	-18.53%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	4.25%	23.63%	31.11	2.75	6.16%	35.06%
HSIC	8.7B	12.3B	-7.72%	-14.36%	20.93	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-14.65%	-39.45%	-12.84	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-11.18%	-30.75%	-62.82	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-3.46%	33.44%	-215.47	8.86	30.82%	65.60%
PDCO	2.3B	6.6B	-3.32%	-1.38%	11.88	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-5.95%	-6.55%	-2.02	0.43	7.73%	-1066.14%
ANIK	408.8M	166.7M	4.91%	6.74%	-4.95	2.45	6.67%	-456.34%
ANGO	250.7M	324.0M	2.96%	-26.18%	-1.3	0.77	-3.19%	-337.41%
APYX	49.5M	52.3M	-10.06%	-59.60%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-19.65%	334.38%	-0.3	0.97	5.77%	8.23%

Vapotherm Inc News

Latest updates

Vapotherm Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	30.1%	19,734,000	15,167,000	16,037,000	17,731,000	18,663,000	13,545,000	12,971,000	21,622,000	22,244,000	38,115,000	20,625,000	32,308,000	40,907,000	30,559,000	35,152,000	19,115,000	13,010,000	10,809,000	11,986,000	12,299,000	11,686,000
Cost Of Revenue	15.1%	10,536,000	9,154,000	9,177,000	11,519,000	13,540,000	11,682,000	10,606,000	13,730,000	14,455,000	19,291,000	11,218,000	15,140,000	20,196,000	15,049,000	17,544,000	9,898,000	7,147,000	5,999,000	6,527,000	7,120,000	6,868,000
Gross Profit	53.0%	9,198,000	6,013,000	6,860,000	6,212,000	5,123,000	1,863,000	2,365,000	7,892,000	7,789,000	18,824,000	9,407,000	17,168,000	20,711,000	15,510,000	17,608,000	9,217,000	5,863,000	4,810,000	5,459,000	5,179,000	4,818,000
Operating Expenses	-12.6%	14,227,000	16,284,000	17,016,000	19,836,000	22,827,000	24,779,000	42,203,000	27,825,000	25,770,000	31,706,000	26,008,000	26,869,000	33,026,000	26,724,000	24,380,000	21,930,000	18,580,000	16,451,000	17,131,000	17,313,000	15,752,000
S&GA Expenses	-15.7%	6,717,000	7,967,000	8,276,000	9,592,000	9,476,000	11,460,000	11,833,000	13,322,000	12,971,000	20,465,000	12,804,000	13,900,000	20,958,000	15,932,000	14,858,000	13,317,000	9,903,000	9,193,000	9,432,000	9,161,000	9,596,000
R&D Expenses	7.6%	3,371,000	3,132,000	3,723,000	3,987,000	4,561,000	4,382,000	6,310,000	5,549,000	4,944,000	3,979,000	4,577,000	4,910,000	4,954,000	4,745,000	3,895,000	3,362,000	3,656,000	3,280,000	3,167,000	3,273,000	2,697,000
EBITDA Margin	28.1%	-0.50	-0.70	-0.90	-1.42	-1.44	-1.37	-0.91	-0.62	-0.46	-0.35	-0.36	-	-	-	-	-	-	-	-	-	-
Interest Expenses	2.2%	4,932,000	4,828,000	4,642,000	4,331,000	3,771,000	3,276,000	2,849,000	1,747,000	635,000	647,000	648,000	665,000	813,000	1,308,000	1,295,000	1,295,000	1,313,000	1,338,000	1,421,000	1,024,000	1,042,000
Income Taxes	311.1%	74,000	18,000	25,000	9,000	-63,000	-8,000	-10,000	92,000	-76,000	-	-	-	-	-	-	-	-146,000	-	-	-	-
Earnings Before Taxes	33.1%	-10,111,000	-15,112,000	-14,763,000	-18,081,000	-21,500,000	-26,209,000	-42,693,000	-22,846,000	-18,636,000	-13,566,000	-17,267,000	-10,407,000	-13,261,000	-	-	-	-12,596,000	-12,765,000	-12,880,000	-12,964,000	-
EBT Margin	17.7%	-0.85	-1.03	-1.22	-1.72	-1.70	-1.57	-1.03	-0.70	-0.53	-0.41	-0.43	-	-	-	-	-	-	-	-	-	-
Net Income	32.7%	-10,185,000	-15,130,000	-14,788,000	-18,090,000	-21,437,000	-26,201,000	-42,683,000	-22,938,000	-18,560,000	-13,566,000	-17,267,000	-10,407,000	-17,184,000	-12,442,000	-8,032,000	-13,844,000	-12,450,000	-12,765,000	-12,880,000	-12,964,000	-12,877,000
Net Income Margin	17.5%	-0.85	-1.03	-1.22	-1.72	-1.70	-1.57	-1.03	-0.70	-0.53	-0.44	-0.46	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-41.1%	-4,957,000	-3,513,000	-7,758,000	-11,038,000	-14,236,000	-21,103,000	-22,949,000	-33,479,000	-17,230,000	-10,478,000	-11,340,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.7%	78.00	81.00	90.00	101	96.00	113	135	181	160	171	174	191	216	202	209	105	112	121	84.00	95.00	97.00
Current Assets	-5.6%	46.00	49.00	57.00	66.00	60.00	76.00	100	126	110	122	124	141	162	180	188	85.00	93.00	103	67.00	78.00	82.00
Cash Equivalents	-32.5%	10.00	14.00	18.00	26.00	16.00	29.00	50.00	73.00	57.00	70.00	81.00	94.00	114	139	148	60.00	72.00	84.00	48.00	59.00	60.00
Inventory	-0.5%	23.00	23.00	25.00	28.00	33.00	36.00	38.00	38.00	37.00	25.00	29.00	27.00	20.00	25.00	19.00	9.00	9.00	11.00	11.00	12.00	14.00
Net PPE	-0.9%	24.00	24.00	24.00	26.00	27.00	26.00	26.00	25.00	22.00	22.00	22.00	22.00	21.00	18.00	17.00	16.00	15.00	14.00	14.00	14.00	13.00
Goodwill	4.4%	1.00	1.00	1.00	1.00	1.00	0.00	1.00	15.00	15.00	14.00	14.00	14.00	16.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-
Liabilities	3.8%	133	128	125	123	124	124	121	127	93.00	89.00	81.00	84.00	102	73.00	70.00	63.00	58.00	56.00	55.00	54.00	46.00
Current Liabilities	18.0%	19.00	16.00	15.00	16.00	20.00	20.00	19.00	23.00	43.00	35.00	27.00	28.00	42.00	30.00	27.00	21.00	16.00	14.00	13.00	12.00	14.00
Shareholder's Equity	-	-	-	-	-	-	-	14.00	54.00	67.00	82.00	93.00	107	114	129	139	41.00	54.00	65.00	29.00	41.00	52.00
Retained Earnings	-1.9%	-548	-538	-522	-508	-490	-468	-442	-399	-376	-358	-344	-327	-316	-299	-287	-279	-265	-252	-240	-227	-214
Additional Paid-In Capital	0.4%	493	491	488	486	462	458	456	454	443	440	438	434	431	428	426	321	319	318	270	268	266
Shares Outstanding	0.5%	6.00	6.00	6.00	6.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	20.00	-	-	-	61.00	-	-	-	543	-	-	-	821,449	-	-	-	302,971	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-32.6%	-3,925	-2,959	-7,354	-10,034	-10,892	-19,126	-19,668	-30,471	-16,149	-8,820	-10,440	-19,962	-7,359	-7,434	-13,953	-10,722	-11,132	-9,644	-9,055	-9,831	-11,422
Share Based Compensation	-8.6%	2,008	2,198	2,585	2,820	2,760	1,681	2,498	3,446	2,569	2,079	2,433	2,685	1,850	1,756	1,377	1,447	895	326	712	1,903	135
Cashflow From Investing	-86.3%	-1,032	-554	-404	-1,004	-3,344	-1,977	-3,281	-3,008	-2,385	-1,658	-900	-2,256	-12,225	-2,105	-2,281	-1,558	-1,615	-968	-1,036	-2,688	-1,183
Cashflow From Financing	-	15.00	-	80.00	20,943	1,157	10.00	-24.00	50,181	5,277	-682	-986	761	-5,775	219	104,197	1,035	849	48,092	-507	11,015	57,575

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VAPO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Income Statement [Abstract]

Net revenue

$ 68,669

$ 66,801

Cost of revenue

40,386

49,558

Gross profit

28,283

17,243

Operating expenses

Research and development

14,213

20,802

Sales and marketing

32,552

46,091

General and administrative

19,260

27,796

Impairment of goodwill

14,701

Impairment of long-lived and intangible assets

1,187

7,676

Loss on disposal of property and equipment

151

568

Total operating expenses

67,363

117,634

Loss from operations

(39,080)

(100,391)

Other (expense) income

Interest expense

(18,733)

(11,643)

Interest income

139

Foreign currency loss

(332)

(239)

Loss on extinguishment of debt

(1,114)

Net loss before income taxes

(58,067)

(113,248)

Provision for income taxes

126

Net loss

(58,193)

(113,259)

Other comprehensive income (loss):

Foreign currency translation adjustments

248

(183)

Total other comprehensive income (loss)

248

(183)

Total comprehensive loss

$ (57,945)

$ (113,442)

Net loss per share - basic

$ (9.64)

$ (33.89)

Net loss per share - diluted

$ (9.64)

$ (33.89)

Weighted-average number of shares used in calculating net loss per share, basic

^[1]

6,037,468

3,341,617

Weighted-average number of shares used in calculating net loss per share, diluted

^[1]

6,037,468

3,341,617

[1]	On August 18, 2023, the Company effected a 1:8 reverse stock split for each share of common stock issued and outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split.

VAPO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets

Cash and cash equivalents

$ 9,725

$ 15,738

Accounts receivable, net of expected credit losses of $160 and $227, respectively

10,672

9,102

Inventories

22,968

32,980

Prepaid expenses and other current assets

3,058

2,081

Total current assets

46,423

59,901

Property and equipment, net

23,703

26,636

Operating lease right-of-use assets

3,372

5,805

Restricted cash

1,109

Goodwill

565

536

Deferred income tax assets

Other long-term assets

2,388

2,112

Total assets

77,617

96,195

Current liabilities

Accounts payable

5,053

2,739

Contract liabilities

1,237

1,216

Accrued expenses and other current liabilities

12,805

15,609

Total current liabilities

19,095

19,564

Long-term loans payable, net

107,059

96,994

Other long-term liabilities

6,797

7,827

Total liabilities

132,951

124,385

Commitments and contingencies (Note 10)

Stockholders' deficit

Preferred stock ($0.001 par value) 25,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022

Common stock ($0.001 par value) 21,875,000 shares authorized as of December 31, 2023 and 2022, 6,165,806 and 3,564,505 shares issued and outstanding as of December 31, 2023 and 2022, respectively

^[1]

Additional paid-in capital

492,764

461,965

Accumulated other comprehensive income (loss)

(157)

Accumulated deficit

(548,195)

(490,002)

Total stockholders' deficit

(55,334)

(28,190)

Total liabilities and stockholders' deficit

$ 77,617

$ 96,195

[1]	On August 18, 2023, the Company effected a 1:8 reverse stock split for each share of common stock issued and outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split.

About Vapotherm Inc

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

CEO	Mr. Joseph F. Army CPA, CPA
WEBSITE	vapotherm.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	261

Vapotherm Inc Frequently Asked Questions

What is the ticker symbol for Vapotherm Inc? What does VAPO stand for in stocks?

VAPO is the stock ticker symbol of Vapotherm Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vapotherm Inc (VAPO)?

As of Fri May 03 2024, market cap of Vapotherm Inc is 7.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VAPO stock?

You can check VAPO's fair value in chart for subscribers.

What is the fair value of VAPO stock?

You can check VAPO's fair value in chart for subscribers. The fair value of Vapotherm Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vapotherm Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VAPO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vapotherm Inc a good stock to buy?

The fair value guage provides a quick view whether VAPO is over valued or under valued. Whether Vapotherm Inc is cheap or expensive depends on the assumptions which impact Vapotherm Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VAPO.

What is Vapotherm Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, VAPO's PE ratio (Price to Earnings) is -0.14 and Price to Sales (PS) ratio is 0.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VAPO PE ratio will change depending on the future growth rate expectations of investors.